Clinical · Comorbidities

About the Comorbidities category

Clinical › Comorbidities type 2 diabetes chronic kidney disease MASH / hepatic steatosis

Pinned Wiki

dr_okonkwoTL4 Moderator7 Mar 2026#1

Community wiki post. Any member at trust level 3 or above can edit this post; every edit is recorded. Last edited by mira.patel on 14 Apr 2026.

15 Apr 2026 — dr_okonkwo: Plain-language pass on the opening paragraph.
14 Apr 2026 — mira.patel: Corrected an arithmetic slip in the second example.

Editors: dr_okonkwo, mira.patel, hana.sato

Staff post. Actions described here are recorded in the public moderation log and may be challenged in Meta.

Type 2 diabetes, hepatic steatosis, sleep apnoea, cardiovascular and renal disease.

This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a note. If the scope described here has drifted from what actually gets posted, edit it rather than starting a topic about it.

What belongs here

Questions specific to comorbidities, with the units and the context stated.
Reports and datasets, with the collection method stated.
Disagreement about the substance, conducted in public.

What belongs elsewhere

Anything urgent belongs in Safety, immediately, and not here.
Anything about how this site works belongs in Meta.
Requests for a maintained page belong in Wiki requests.

Before posting, it is worth checking the documentation commons and this category's tag pages. A great deal of what gets asked here has a maintained answer with a review date on it, which is more reliable than a two-year-old reply.

0 likes 5mo

j.mwangiTL4 Moderator24 Apr 2026#2

Staff post. Actions described here are recorded in the public moderation log and may be challenged in Meta.

Moderation notes for this category, so that nothing about how it is run is a surprise.

Topics get moved into and out of here regularly. A move is not a judgement — the category tree is not obvious from outside and putting a question in the wrong place is expected. When I move something I say so in the topic and the action appears in the public log with the guideline cited.

The two guidelines that come up most often in this category are R2, on supplying a source when asked, and R7, on category placement. Neither is used punitively.

24 likes 3mo

k.haddadTL2 Moderator29 May 2026#3

As a member rather than staff: the most useful thing I did when I started reading this category was to work through the tag pages rather than the topic list. The topic list shows you what is recent. The tags show you what is settled.

11 likes 2mo

buffer_marginTL3Regular29 Jun 2026#4

Suggestion for the wiki post above: it would be worth linking the two or three most-referenced topics in this category directly, since new members reliably ask for exactly those. Happy to make the edit myself if nobody objects, with a revision note.

3 likes 29d

crossover_entryTL3Regular27 Jul 2026#5

dr_okonkwo, post #1: Type 2 diabetes, hepatic steatosis, sleep apnoea, cardiovascular and renal disease. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a note. If the scope described here has drifted from what actually gets posted, edit it rather than starting a topic about it.… Go to post

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

0 likes in reply to #1 12h

This topic was referenced in

Second pass at: Obstructive sleep apnoea and a hard endpoint in this classClinical › Comorbidities · 2 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Second pass at: Obstructive sleep apnoea and a hard endpoint in this class Clinical › Comorbidities type 2 diabetes obstructive sleep apnoea MASH / hepatic steatosis chronic kidney disease Second pass at: Obstructive sleep apnoea and a hard endpoint in this class — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The…		2	726	14mo
[2026 update] Gastro-oesophageal reflux: improving or worsening? Clinical › Comorbidities chronic kidney disease MASH / hepatic steatosis PCOS blood pressure Solved Asking directly, because I could not find a straight answer: Gastro-oesophageal reflux: improving or worsening? General question, not a request for advice about my own care — I know the difference and I would…		3	782	13mo
[2026 update] Cardiovascular risk: reading the outcome trials as a set Clinical › Comorbidities PCOS type 2 diabetes chronic kidney disease blood pressure Posting this under the heading it deserves: Cardiovascular risk: reading the outcome trials as a set Everything below is what sits behind that. Asking about a population rather than about a person. The…	+99	103	32k	11mo
Hepatic steatosis: what the MASH trial evidence supports — one year on Clinical › Comorbidities MASH / hepatic steatosis obstructive sleep apnoea chronic kidney disease blood pressure Solved On the subject in the title: Hepatic steatosis: what the MASH trial evidence supports — one year on Working notes rather than a conclusion. General question, not a request for advice about my own care — I…		2	4.1k	6mo
Revisiting: Gallbladder disease risk with rapid weight loss Clinical › Comorbidities MASH / hepatic steatosis chronic kidney disease PCOS obstructive sleep apnoea Revisiting: Gallbladder disease risk with rapid weight loss Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…		2	2k	9mo

Related topics — sharing the tags type 2 diabetes, chronic kidney disease, MASH / hepatic steatosis

Topic	Participants	Replies	Views	Activity
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Compounds › Semaglutide STEP programme type 2 diabetes randomised trial effect size Posting this under the heading it deserves: Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022)…	+125	132	39k	16mo
How to ask for a dose change without antagonising anyone Clinical › Prescriber conversations telehealth beginner friendly type 2 diabetes Solved The question in the title: How to ask for a dose change without antagonising anyone I will give what I have already checked below so nobody repeats it. Asking about a population rather than about a person.…	+19	23	2.9k	23mo
Pregnancy and pregnancy planning: contraindication and washout Clinical › Special populations pregnancy & planning bariatric surgery history chronic kidney disease disordered eating Closed Posting this under the heading it deserves: Pregnancy and pregnancy planning: contraindication and washout Everything below is what sits behind that. General question, not a request for advice about my own…	+111	122	2.4k	3mo
Older adults, sarcopenia risk, and the trade-off nobody quantifies — the long version Clinical › Special populations older adults chronic kidney disease adolescents disordered eating Older adults, sarcopenia risk, and the trade-off nobody quantifies — the long version — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a…	+64	69	15k	7mo
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile — what changed since Compounds › Semaglutide semaglutide SELECT trial type 2 diabetes STEP programme Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile — what changed since — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA ,…	+6	10	6.1k	8mo

Sponsored PeptideMeter — peptide analytics and supplier verificationPurity analysis and structured supplier verification, published as dated records rather than scores. Referenced throughout our sourcing documentation.View analytics →